POSTER: AML-418 Recommended Phase 2 Dose (RP2D) Determination of Bleximenib in Combination With Venetoclax+Azacitidine (VEN+AZA): Phase Ib Study in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) With KMT2A or NPM1 Alterations | Publicación